Print this Content
Email this Content

Appointed: 2006

Stephen Nicholls, M.B.B.S., Ph.D.

Stephen Nicholls, M.B.B.S., Ph.D.

Department: Cell Biology
Associate Staff
Location: Cleveland Clinic Main Campus
Mail Code JJ65
9500 Euclid Avenue
Cleveland, OH 44195
WorkPhone:(216) 444-2678

Biographical Sketch

Stephen J. Nicholls, MBBS (Bachelor of Medicine/Surgery), PhD, is Medical Director of Intravascular Ultrasound and Angiography Core Laboratories at Cleveland Clinic and Clinical Director of the Cleveland Clinic Center for Cardiovascular Diagnostics and Prevention. Dr. Nicholls is also Associate Director of the Cleveland Clinic Coordinating Center for Clinical Research and Assistant Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. He holds dual faculty appointments in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine in the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic, and the Department of Cell Biology in the Learner Research Institute.

Dr. Nicholls received his medical degree from the University of Adelaide in Australia. Following residency in internal medicine at the Royal Adelaide Hospital, he completed a clinical fellowship in cardiovascular medicine at John Hunter Hospital. He subsequently undertook his doctoral studies, focusing on the protective properties of high-density lipoproteins (HDL or “good cholesterol”) at the Heart Research Institute in Sydney. Following this training, Dr. Nicholls completed a postdoctoral fellowship in plaque imaging at Cleveland Clinic prior to his faculty appointment.

He is a fellow of the Royal Australasian College of Physicians and American College of Cardiology and a member of the American Heart Association. He received the Helen May Davies Research Award from the National Heart Foundation of Australia, the Young Investigator Award at the 13th International Symposium on Atherosclerosis and was a finalist for the Samuel A. Levine Clinical Young Investigator Award at the 2005 Annual Scientific Sessions of the American Heart Association.

He has authored more than 150 original manuscripts, meeting abstracts and book chapters. His current research interests include the functional properties of HDL, the role of inflammation and oxidative stress in atherogenesis and the development of new imaging modalities to assess factors that influence the natural history of atherosclerosis. He plays a lead role in clinical trials that employ intravascular ultrasound to investigate the impact of novel anti-atherosclerotic therapies.

Professional Highlights

  • Young Investigator Award 13th International Symposium on Atherosclerosis
  • Finalist, Samuel A. Levine Clinical Young Investigator Award, 2005 Scientific Sessions of the American Heart Association

Education & Fellowships

Fellowship - Cleveland Clinic
Postdoctoral Research Fellow
Cleveland, OH USA
2006
Fellowship - Heart Research Institute
Research Fellow, Lipid Research Group
Sydney Australia
2004
Doctorate - University of Adelaide
Medical Biochemistry
Adelaide Australia
2004
Fellowship - Royal Adelaide Hospital
Research Fellow, Lipid Research Laboratory
Adelaide Australia
2002
Fellowship - John Hunter Hospital
Cardiovascular Medicine
Newcastle Australia
2001
Residency - Royal Adelaide Hospital
Internal Medicine
Adelaide Australia
1998
Internship - Royal Adelaide Hospital
Internal Medicine
Adelaide Australia
1995
Medical School - University of Adelaide Faculty of Medicine
Adelaide Australia
1995

Specialty Interests

preventive cardiology, cardiovascular imaging

Memberships

  • American College of Cardiology
  • American Heart Association
  • Royal Australasian College of Physicians

Treatment & Services

  • Cardiovascular Imaging
  • Preventive Cardiology

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 8/5/2008, Dr. Nicholls has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting. Dr. Nicholls receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:

AstraZeneca Pharmaceuticals LP

Roche

Takeda Pharmaceuticals

Sanofi-Aventis US Inc.

Languages Spoken

  • English